company-header-background
Discovery

 

The physiological, cellular, and/or genetic basis of a disease is studied to identify potential therapeutic targets. 

 

Development

Once a potential target has been identified, researchers will then screen thousands of APIs, excipients and/or formulations for potential candidates that act on this target.

 

After early testing, however, only a small number of compounds look promising and call for further study. 

 

We are in the age of cell therapy and gene therapy with bioprocessing being a key element. Being able to affect disease at the molecular level is the key, and nanomedicine is a fundamental technology for ushering in the next wave of genetic and molecularly targeted therapeutics.


The NanoAssemblr® Product Suite and Formulation Solutions

NanoAssemblr Spark

 

The NanoAssemblr® Spark™ produces microlitre volumes of nanomedicines for discovery research.

NanoAssemblr Benchtop

 

 

The NanoAssemblr® Ignite manufactures 1 – 15 mL of nanomedicine per run for nanomedicine development programs.

Formulation Solution Experts

 

 

 

To rapidly reach the formulation proof of concept stage PNI offers highly qualified scientist with extensive formulation development experience through our Formulation Solutions Team.                                                                                                                                           

 

At every step, our multidisciplinary experts will partner with you to build affirm scientific foundation for the work ahead.


Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Selection

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. Ferlenghi, R. Johnson, C.W. Rob...

Read More 阅读更多

Publication - Abstract

May 08, 2020

Vaccines

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner and Y. Perrie

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to Liposomes

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Romano, D.T. O'Hagan, U. D'Oro, ...

Read More 阅读更多

Publication - Abstract

December 31, 2019

Vaccines

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Abstract

May 31, 2019

Vaccine

mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerated in Healthy Adults ...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith, Ö. Almarsson, H.S. Pujar, M....

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid Nanoparticle-mediated siRNA Delivery for Safe Targeting of Human CML In Vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, M. Heuser et al.

Read More 阅读更多
Resource Center 资源中心
MENU
菜单
X
X